AstraZeneca to Invest USD2.5 Billion in New R&D Center in Beijing
Since 2023, AstraZeneca has invested more than USD1.7 billion to expand its production in China, including spending USD750 million to build a new inhaler production base in Qingdao, eastern Shandong province, and USD475 million for a small molecule drug factory in Wuxi, eastern Jiangsu province.
AstraZeneca announced an investment of $2.5 billion in Beijing to establish its sixth global strategic R&D centre together with major research and manufacturing agreements that will further advance ...
Drugmaker AstraZeneca has agreed to buy Belgium-based biotechnology firm EsoBiotec for up to $1 billion, it said on Monday, ...
Tallying up a wide range of investments, AstraZeneca said it is pumping $2.5 billion into Beijing. The figure includes ...
Shares of Harbour BioMed soared after the Chinese biopharmaceutical firm announced a collaboration with U.K. pharma giant AstraZeneca, which plans to invest $2.5 billion in China. The stock rose as ...
AstraZeneca has tapped Korea's Alteogen to develop subcutaneous cancer drugs. Taiho Pharmaceutical is paying $400 million to ...
Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and ...
AstraZeneca scrapped a £450m vaccine plant in Liverpool after the UK government missed a critical funding deadline. The ...
AstraZeneca is hopping on the pickleball craze for the latest iteration of its Stepping Back Out campaign for asthma treatment Fasenra.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback